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Human cytomegalovirus (HCMV) is a widespread pathogen that establishes lifelong latent infection facilitated by numerous mechanisms for
modulating the host immune system. The UL111A region of the HCMV genome encodes a homolog of human cellular IL-10 (hIL-10). The viral
cytokine, cmvIL-10, exhibits many of the immunosuppressive properties of hIL-10. However, hIL-10 is also known to have stimulatory effects on
B lymphocytes. We found that cmvIL-10 has the ability to enhance B cell proliferation, despite having only 27% sequence identity to hIL-10.
Treatment with cmvIL-10 stimulated autocrine production of hIL-10 by B lymphocytes and led to activation of the latent transcription factor Stat3.
In contrast, LAcmvIL-10, a truncated protein resulting from an alternatively spliced transcript in latently infected cells, did not stimulate B cell
proliferation, Stat3 activation, or hIL-10 production. These results provide insights into the biological activity of the full-length and latency-
associated viral cytokines and suggest different roles for each in HCMV infection.
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Human cytomegalovirus (HCMV) is ubiquitous in the
general population, causing acute, chronic, or latent infection.
Once known as “salivary gland virus”, HCMV was first isolated
from the salivary glands and kidneys of a dying infant with
greatly enlarged cells, or cytomegalic inclusion bodies, in af-
fected tissues (Brennan, 2001). In most individuals, primary
infection with HCMV is asymptomatic; however, serious symp-
toms can occur in patients with compromised immune systems
(Britt, 1996). The HCMV genome is among the largest of
mammalian DNA viruses (N230 kb), and it encodes more than
200 different proteins (Murphy et al., 2003). A significant part of
this coding potential is devoted to proteins that are not required
for virus replication in culture, but instead, to proteins that
facilitate immune evasion and virus persistence in vivo. Among⁎ Corresponding author. Department of Biology, University of San Francisco,
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doi:10.1016/j.virol.2007.11.031these immunomodulatory proteins is the product of the UL111A
region, which encodes a protein with 27% amino acid sequence
identity to human interleukin-10 (hIL-10) (Kotenko et al., 2000).
IL-10 is a multi-functional cytokine that is important in the
regulation of the immune response (Moore et al., 2001). Secreted
by numerous cell types, including macrophages, T cells, and B
cells, hIL-10 is normally produced late in the immune response to
a pathogen when it functions to attenuate the response through
suppression of inflammatory cytokines. Exploitation of hIL-10
and its immunomodulatory properties is a common strategy for
intracellular pathogens. Bacteria like Listeria monocytogenes and
Mycobacterium tuberculosis induce production of cellular hIL-10
to avoid immune clearance (Redpath et al., 2001), while
numerous viruses encode homologs of hIL-10, including
HCMV, Epstein–Barr virus (Hsu et al., 1990), equine herpesvirus
2 (Rode et al., 1993), and the Orf poxvirus (Fleming et al., 1997).
HCMV-encoded IL-10 is unique among these viral homologs
because it has significantly lower sequence identity to hIL-10, and
because it is encoded as a discontinuous open reading frame
containing two introns (Kotenko et al., 2000). Intriguingly, the
presence of introns in the gene encoding cmvIL-10 allows for the
Fig. 1. cmvIL-10 stimulates proliferation of B cells. (A) Daudi B cells were
cultured in control medium containing 10% FCS and 5 ng/ml rhIL-4 or medium
supplemented with 30 ng/ml recombinant hIL-10, cmvIL-10 or LAcmvIL-10.
Control cells received an equivalent volume of the mock protein preparation.
Proliferation was measured at the indicated times using the luciferin-based Cell
TiterGlo Assay (Promega); the resulting light emitted was recorded in relative
light units (RLUs) and is proportional to cell number. This figure is representative
of three separate experiments. (B) Dose-dependent stimulation of B cells by
cmvIL-10. Daudi B cells were cultured in the presence of the indicated doses of
hIL-10, cmvIL-10 or LAcmvIL-10. After 72 h, the Cell Titer Glo assay was used
to quantify cell number. (n=3 separate experiments). Error bars indicate standard
deviation from the mean value for three replicate data points.
165J.V. Spencer et al. / Virology 374 (2008) 164–169possibility of alternative splicing, and this has been documented to
occur in latently infected granulocyte–macrophage progenitor
cells (Jenkins et al., 2004). The UL111A region latency-associated
(LA) transcript differs from full-length cmvIL-10 transcripts in that
it contains only one intron, resulting in an in-frame stop codon at
nucleotide position 160171 (strain AD169). The LAcmvIL-10
protein product is co-linearwith cmvIL-10 for the first 127 residues
and then diverges in sequence at the truncated C-terminal domain
(139 amino acids total compared to 175 for full-length cmvIL-10).
Whereas full-length cmvIL-10 exhibits a broad range of inhibitory
functions associated with hIL-10, including inhibition of PBMC
proliferation, suppression of inflammatory cytokine synthesis,
reduction of class II MHC expression, and impairment of dendritic
cell maturation expression (Chang et al., 2004; Raftery et al., 2004;
Spencer et al., 2002), the immunosuppressive activities of
LAcmvIL-10 appear to be much more restricted. To date,
LAcmvIL-10 has been shown only to induce down-regulation of
class II MHC on myeloid cells, and this was found to occur
independently of the cellular IL-10 receptor (B.S., unpublished
data).
In addition to its potent anti-inflammatory properties, hIL-10
also plays a key role in promoting the growth and differentiation
of B cells (Go et al., 1990; Moore et al., 2001; Rousset et al.,
1992). Such stimulatory activity, however, has not yet been
reported for cmvIL-10 or LAcmvIL-10. Considering their
relatively low sequence identity with hIL-10, it seems likely
that these viral cytokines might preserve only a distinct subset of
hIL-10 activities (i.e., those that are immunosuppressive) in
order to produce an environment that is advantageous for the
virus. Here, we investigated whether cmvIL-10 had retained the
ability to promote B cell proliferation. Our results show that
cmvIL-10 stimulates both B cell growth and autocrine
production of cellular hIL-10, whereas LAcmvIL-10 does not.
These findings provide additional functional characterization of
cmvIL-10 and highlight functional differences between the full-
length and truncated HCMV IL-10 homologues.
Results
To investigate whether cmvIL-10 had retained the ability to
stimulate B cell proliferation, we employed the human B cell
lymphoma Daudi cell line. Daudi B cells were cultured in RPMI
containing 10% fetal calf serum and supplemented with 5 ng/ml
recombinant human IL-4. In control cells, significant cell growth
was observed over a 72-h time period. When treated with cmvIL-
10, however, cell growth was increased by approximately 45%
after 48 h (Fig. 1A). By 72 h, cmvIL-10 treatment had increased
proliferation by nearly 60% over the basal rate. This outcome was
similar to treatment with the same dose of hIL-10, which caused B
cell proliferation to increase to levels of 64% higher than con-
trol cells. Overall, B cell proliferation was enhanced in a dose-
dependentmanner, as shown in Fig. 1B, confirming that cmvIL-10
has comparable stimulatory activity to the human cellular
cytokine. In contrast, LAcmvIL-10 treatment did not increase B
cell growth by more than 5–10% over basal levels at any dose or
time point, suggesting that the latent formof the viral cytokinemay
have distinct biological functions from the full-length cmvIL-10.Previous work has demonstrated that the immune suppres-
sive effects of cmvIL-10 are mediated through engagement of
the cellular IL-10 receptor (Kotenko et al., 2000; Spencer, 2007;
Spencer et al., 2002). One of the earliest outcomes resulting
from ligand engagement of the IL-10R is activation of the latent
transcription factor Stat3 by the receptor-associated kinase
JAK1 (Moore et al., 2001). To examine whether the stimulation
of B cell growth by cmvIL-10 also led to activation of Stat3,
Daudi B cells were treated with varying doses of hIL-10,
cmvIL-10, or LAcmvIL-10 for 15 min, then cell lysates were
analyzed by SDS–PAGE and Western blotting. Stat3 activation
induced by cmvIL-10 was evident from the phosphorylation of
tyrosine 705, as shown in Fig. 2A. Comparable results were
observed with hIL-10, confirming that cmvIL-10 has retained
the capacity to mimic the activation properties of hIL-10. In
contrast, LAcmvIL-10 did not induce Stat3 activation in B cells.
When cells were treated with both cmvIL-10 and LAcmvIL-10
in combination, Stat3 phosphorylation was observed (data not
shown), confirming that LAcmvIL-10 did not actively inhibit or
interfere with Stat3 activation.
Although previous studies demonstrating biological function
of full-length cmvIL-10 were performed with a recombinantly
expressed protein containing a 6X-histidine epitope tag (Spencer
et al., 2002), our current work has employed commercially
Fig. 2. cmvIL-10 activates Stat3 via binding to the cellular IL-10 receptor (A). Daudi B cells were treated with the indicated doses (ng/ml) of hIL-10, cmvIL-10 or
LAcmvIL-10, then cell lysates were analyzed by Western blotting with antibodies to total Stat3 or phosphorylated Stat3 (Y705). Total Stat3 antibodies detect
unmodified protein and serve as a loading control to ensure all lanes contained the same amount of protein. Antibodies were from Cell Signaling Technology and
detection was via the Western Breeze system (Invitrogen). The well labeled Mock was treated with the volume of mock protein preparation equivalent to the highest
dose of LAcmvIL-10. This result is representative of three separate experiments. (B) Stat3 phosphorylation in Daudi B cells treated with either 10 ng/ml of his-tagged
cmvIL-10 or commercial cmvIL-10 from R&D Systems.
Fig. 3. cmvIL-10 induces endogenous cellular hIL-10 production. (A) Daudi B
cells were treated with the indicated concentrations of cmvIL-10, LAcmvIL-10,
or mock protein for 48 h, and then supernatants were assayed by sandwich
ELISA (R&D Systems). Shown are mean concentrations from triplicate cultures
and results are representative of two separate experiments. (B) Inhibition of
TNFα by LAcmvIL-10. THP-1 myeloid cells were stimulated with LPS in the
presence or absence of hIL-10, cmvIL-10 or LAcmvIL-10. After 24 h, super-
natants were collected and analyzed by sandwich ELISA. Shown are mean
concentrations from triplicate cultures and results are representative of three
separate experiments. Error bars indicate standard deviation from the mean
value for three replicate data points. Statistical analysis showed that TNFα levels
decreased significantly in the presence of hIL-10, cmvIL-10 or LAcmvIL-10
(⁎Pb.005).
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Because the LAcmvIL-10 protein produced here still contains
the his-tag, we wished to confirm that the epitope tag did not
interfere with the stimulatory properties of the viral cytokine. As
shown in Fig. 2B, Stat3 activation was observed in Daudi B cells
treated with either purified recombinant his-tagged cmvIL-10 or
with commercial cmvIL-10 protein (without a his-tag) pur-
chased from R&D Systems. The results demonstrate that the his-
tagged cytokine has the same biological functions as the com-
mercially available purified cmvIL-10 and rule out the
possibility that LAcmvIL-10 fails to activate Stat3 due to inter-
ference from the his-tag. Taken together, these experiments
indicate that while cmvIL-10 shares functions of hIL-10, in-
cluding stimulation of B cells, the latency-associated form of the
viral cytokine differs significantly.
Given that hIL-10 is a growth factor for B lymphocytes, we
asked whether cmvIL-10 treatment could stimulate production of
hIL-10 from Daudi B cells. Cells were treated with varying doses
of cmvIL-10, LAcmvIL-10, or mock protein preparation for 48 h,
and then the supernatants were harvested and analyzed for the
presence of hIL-10 by ELISA. As shown in Fig. 3A, hIL-10
production by Daudi B cells was increased in a dose-dependent
manner by cmvIL-10 treatment. Basal levels of hIL-10 production
were increased by nearly sevenfold in the presence of 50 ng/ml
cmvIL-10. No detection of cmvIL-10was observed using the hIL-
10 ELISA reagents, eliminating the possibility that the increase
was due to antibody cross reactivity with the viral cytokine added
to the culture medium. Once again, no stimulatory activity was
detected for LAcmvIL-10, which did not trigger autocrine
production of hIL-10 at any dose.
Becausewe failed to observe stimulatory activity byLAcmvIL-
10, we wished to demonstrate that the protein was in fact bio-
logically active. Since both hIL-10 and cmvIL-10 are potent
inhibitors of monocyte cytokine synthesis, we tested the ability
of LAcmvIL-10 to inhibit TNFα production by human myeloid
167J.V. Spencer et al. / Virology 374 (2008) 164–169cells. THP-1 myeloid cells were treated with the indicated
cytokines prior to stimulation with 10 ng/ml LPS for 24 h. As
shown in Fig. 3B, control cells produced a significant amount of
TNFα when stimulated with LPS. In comparison, the amount of
TNFα produced was decreased by about 90%when the cells were
pre-incubatedwith either hIL-10 or cmvIL-10 and about 60%with
LAcmvIL-10. These data demonstrate that together with hIL-10
and cmvIL-10, LAcmvIL-10 is a biologically active protein with
immune suppressive function on myeloid lineage cells.
Finally, since cmvIL-10 induced production of cellular hIL-10
from B cells, we asked whether there was any impact on the level
of expression of the IL-10 receptor (IL-10R). Daudi B cells were
incubated with cmvIL-10 or LAcmvIL-10 for 48 h, then stained
with antibodies to the cellular IL-10 receptor and examined via
flow cytometry. Cells treated with cmvIL-10 exhibited a modest
increase in IL-10R expression (Fig. 4). The mean fluorescence
intensity increased by nearly 40% over control mock-treated cells,
suggesting that more receptors were present on the cell surface
after incubation with the viral cytokine. Treatment with
LAcmvIL-10 did not significantly impact IL-10R surface levels.
For comparison, the impact of the viral cytokines on two other cell
surface molecules was also examined. CD19 is a B cell marker,
and the amount of this protein in the cell surface was the same
regardless of cell treatment. HLA-DR is a haplotype of the human
MHC class II complex, and this protein was also found to be
highly expressed on Daudi B cells. Despite reports that cmvIL-10
and LAcmvIL-10 can reduceMHC expression onmonocytes andFig. 4. Up-regulation of cellular IL-10R by cmvIL-10. A) Daudi B cells were
treated with 50 ng/ml cmvIL-10 (solid line), LAcmvIL-10 (dashed line), orMock
preparation (control, gray shaded histogram) for 48 h before staining with the
indicated phycoerythrin-conjugated antibodies and analysis by flow cytometry.
The dotted line indicates mock-treated cells stained with the appropriate isotype
control antibody, and relative fluorescence intensity is shown on the X-axis in log
scale. These results are representative of three separate experiments.dendritic cells (Chang et al., 2004; Raftery et al., 2004; Spencer et
al., 2002), no impact on MHC class II levels was observed here.
These results demonstrate that cmvIL-10 causes up-regulation of
the cellular hIL-10R without affecting CD19 or MHC class II
expression levels.
Discussion
Utilization of IL-10 is a common mechanism for intracellular
pathogens to suppress or delay the immune response and establish
productive infection in the host (Redpath et al., 2001). cmvIL-10
has previously been demonstrated to inhibit PBMC proliferation,
suppress inflammatory cytokine production, and down-regulate
MHC expression (Spencer et al., 2002). Recent studies also show
that cmvIL-10 inhibits dendritic cell maturation and migration
(Chang et al., 2004; Raftery et al., 2004), effects that are likely
to significantly hamper the cell-mediated immune response to
HCMV infection. Our study demonstrates that cmvIL-10 has the
ability to stimulate B cell proliferation and induce enhanced
production of endogenous hIL-10. This represents the first report
of stimulatory activity toward B cells associated with the HCMV
encoded IL-10 homolog. This suggests that not only is the
immune response toHCMVinfection suppressedwhen cmvIL-10
is present, but the viral cytokinemay actually initiate a Th2 type of
response in the host. Since humoral immunity is less effective at
controlling virus infection than the cell-mediated response,
stimulation of B cells by cmvIL-10 may delay the appropriate
anti-viral immune response, allowing HCMV time to establish
persistent infection. Although the study would have been more
physiologically relevant had it been conducted with primary B
cells, attempts to isolate primary B cells from human blood
samples were hindered by low yields. As a result, we focused our
efforts on the effect of the viral cytokines on B cell lines. While
the data shown here are for the Daudi B cell line, we also ob-
served that cmvIL-10 could stimulate proliferation and Stat3
activation for three other B cell lines: Jijoye (EBV-positive B cell
lymphoma), Ramos (EBV-negative B cell lymphoma) and JMI
(EBV negative pre-B cell lymphoma) cell lines (data not shown).
While we cannot confirm that cmvIL-10 would have these same
stimulatory effects on primary B cells, the observation that several
different B cell lines were similarly affected supports the notion
that the viral cytokine is likely to stimulate B cells in vivo in the
context of viral infection.
Both inhibitory and stimulatory effects of IL-10 are mediated
through the cellular IL-10 receptor. Despite their considerable
sequence divergence, the crystal structure revealed that cmvIL-10
and hIL-10 share similar contact points with and binding affinities
for the cellular IL-10 receptor (Jones et al., 2002). Engagement of
the IL-10 receptor by cmvIL-10 has previously been shown to
activate Stat3 in various cell types (Kotenko et al., 2000; Spencer,
2007). In B lymphocytes, we have observed activation of Stat3
that correlateswith cmvIL-10 stimulatory activity. It is of note that
LAcmvIL-10 did not induce Stat3 activation. This result is not
surprising considering that the truncated latency-associated
protein lacks a significant number of IL-10R contact residues
located at the carboxy-terminus of the full-length cmvIL-10 pro-
tein (Jones et al., 2002). This is also consistent with the finding
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namely down-regulation of class II MHC expression on myeloid
cells, occurs in an IL-10R independent fashion. Further
investigation will be required to identify the alternative receptor
and determine the mechanism bywhich LAcmvIL-10 contributes
to class II MHC down-regulation.
Although we observed up-regulation of both hIL-10 produc-
tion and the expression level of the cellular IL-10 receptor, no
change inMHC class II protein levels was observed on B cells in
this study. Previous reports indicate that hIL-10 increases MHC
class II expression, although this activity was not conserved by
the Epstein–Barr virus encoded vIL-10 (Go et al., 1990). Given
the many strategies employed by HCMV for interfering with the
MHC antigen presentation system (Basta and Bennink, 2003;
Hengel et al., 1998; Mocarski, 2002), it is perhaps to be ex-
pected that the viral cytokine would fail to increaseMHC class II
expression.
Human IL-10 plays a pivotal role in regulation of the immune
response and greatly impacts the outcome of virus infection.
Recent evidence suggests that the presence of IL-10 is one of the
single most important factors contributing to ineffective antiviral
responses, and early neutralization of IL-10 activity can prevent
persistent virus infection (Brooks et al., 2006). The presence of a
viral IL-10 homolog encoded in the genome of HCMVand other
viruses is clearly a significant benefit for the establishment of
latency and/or persistent infection. Our results demonstrate that
not only does cmvIL-10 dampen the inflammatory immune
response but it can also stimulate the humoral response, leading
to even greater interference with virus clearance. The existence
of a second, latency-associated form of cmvIL-10 that lacks these
immunomodulatory properties suggests that these viral cytokines
may play a role in the establishment of or reactivation from
latency. HCMV has capitalized on the immunoregulatory proper-
ties associated with hIL-10 in three ways: enabling the full
spectrum of IL-10 biological activities by triggering production of
the human cytokine, invoking a smaller subset of these properties
through production of cmvIL-10 during productive infection, and
finally, use of a more limited range of immunosuppressive
activities through production of LAcmvIL-10 during latent in-
fection. Future studies will be required to investigate the full range
of biological activities of LAcmvIL-10 and to understand the




Daudi human B cell lymphoblastoma cells were obtained from
American Type Culture Collection (ATCC, Manassas, VA) and
maintained in RPMI 1640 tissue culture medium (Mediatech, Inc.,
Herndon, VA) supplemented with 4.5 g/L glucose, 1.5 g/L sodium
bicarbonate, 2 mM L-glutamine, 1 mM sodium pyruvate, 10 mM
HEPES and 10% fetal bovine serum (FBS; Atlanta Biologicals,
Atlanta, GA) in a 37 °C incubator with a humidified 5% CO2
environment. THP-1 human monocytic cells (ATCC) were like-
wise maintained in RPMI supplemented as described above. Puri-fied recombinant human IL-4, IL-10 and cmvIL-10 were
purchased from R&D Systems (Minneapolis, MN). LAcmvIL-
10 and cmvIL-10 were purified by ion-exchange chromatography
from lysates of bacterial cells expressing plasmid encoded
histidine-tagged cytokine. The concentration of the purified protein
was determined via spectrophotometry. Preparations from mock
transformed bacterial cell lysates were used as a control.
Cell proliferation
Cells were plated at 5×104 per well in white 96-well plates in
the presence or absence of cytokine as indicated. Cell growth was
measured using the Cell Titer Glo Kit (Promega, Madison, WI).
Briefly, a luciferin substrate added to each well was converted to
oxyluciferin in the presence of O2 and ATP. The light produced
was measured using a Veritas Microplate Luminometer (Turner
Biosystems, Sunnyvale, CA) and was proportional to the amount
of ATP present, reflecting the number of viable cells in the well.
Western blotting
Cells were treated with cytokine as indicated, then harvested
and incubated with cell lysis buffer (150 mM NaCl, 20 mM
HEPES, 1% Triton X-100, 1 mM Na3VO4, 1 mM EDTA, and
1 mM PMSF) at 4 °C for 30 min. Cell lysates were clarified by
centrifugation, and the supernatants were then analyzed by SDS–
PAGE and subsequent Western blotting with polyclonal anti-
serum directed against either total Stat3 or phospho-Stat3-(Y705)
(Cell Signaling Technologies, Danvers, MA) according to the
manufacturer's instructions. Alkaline phosphatase-conjugated
goat anti-rabbit secondary antibody (Anaspec, San Jose, CA)
andWesternBlue Substrate (Promega)were utilized for detection.
ELISA
Following cell treatment, supernatants were collected and
human cellular IL-10 levels analyzed via sandwich ELISA
(R&D Systems). The assay was carried out according to the
manufacturer's instructions; resulting samples were analyzed at
450 nm, and cytokine levels determined by linear regression
analysis using a standard curve. TNFα levels were similarly
measured via sandwich ELISA (R&D Systems) following LPS
(lipopolysaccharide; Sigma-Aldrich, St. Louis, MO) and cyto-
kine treatment of THP-1 cells. Statistical analysis was per-
formed with a two-tailed, paired Student's t test.
Flow cytometry
Cells were treated for 48 h, then washed and suspended in
FACS buffer (PBS+0.5% BSA+1 mM EDTA) before staining
with phycoerythrin conjugated antibodies specific for CD19, IL-
10 receptor, HLA-DR (Class II MHC) or the appropriate isotype
control (IgG2a for CD19 and HLA-DR, IgG1 for IL-10R; BD
Pharmingen, San Diego, CA). After staining for 1 h on ice, cells
were washed twice and then resuspended in 300 μl FACS buffer.
Data was collected immediately with the BD FACSCalibur and
analyzed using CellQuest Pro software.
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